| ContextLogic Inc. (LOGC) Q1 2025 Earnings Call Transcript |
ContextLogic Inc. (NASDAQ:LOGC ) Q1 2025 Earnings Conference Call May 9, 2025 5:00 PM ET Company Participants Rishi Bajaj - Chief Executive Officer Conference Call Participants Operator Good afternoon ladies and gentlemen and thank you for standing by. Welcome to ContextLogic's First Quarter 2025 Earnings Conference Call. |
seekingalpha.com |
2025-05-09 23:31:36 |
Czytaj oryginał (ang.) |
| ContextLogic Inc. Reports First-Quarter 2025 Financial Results |
OAKLAND, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (Nasdaq: LOGC) (“ContextLogic,” the “Company,” “we” or “our”) today reported its financial results for the quarter ended March 31, 2025. |
globenewswire.com |
2025-05-09 20:00:00 |
Czytaj oryginał (ang.) |
| ContextLogic to Announce First Quarter 2025 Results on May 9, 2025 |
OAKLAND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (Nasdaq: LOGC), (“ContextLogic” or the “Company”) today announced it will report its first quarter 2025 financial results after the close of market on Friday, May 9, 2025. |
globenewswire.com |
2025-05-06 12:00:00 |
Czytaj oryginał (ang.) |
| ContextLogic Inc. (WISH) Q4 2024 Earnings Conference Call Transcript |
ContextLogic Inc. (WISH) Q4 2024 Earnings Conference Call March 12, 2025 5:00 PM ET Company Participants Ted Goldthorpe - Chairman Rishi Bajaj - CEO Conference Call Participants Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to today's call announcing the strategic investment in ContextLogic by BC Partners. |
seekingalpha.com |
2025-03-12 22:30:25 |
Czytaj oryginał (ang.) |
| ContextLogic Inc. Reports Fourth-Quarter and Fiscal Year 2024 Financial Results |
OAKLAND, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (Nasdaq: LOGC) (“ContextLogic,” the “Company,” “we” or “our”) today reported its financial results for the quarter and fiscal year ended December 31, 2024. |
globenewswire.com |
2025-03-12 18:00:00 |
Czytaj oryginał (ang.) |
| ContextLogic to Announce Fourth Quarter and Full Year 2024 Results and Provide Strategic Update on March 12, 2025 |
OAKLAND, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (Nasdaq: LOGC), (“ContextLogic,” the “Company,” “we” or “our”) today announced it will report its fourth quarter and full year 2024 financial results after the close of market on Wednesday, March 12, 2025. ContextLogic's CEO Rishi Bajaj and its Chairman Ted Goldthorpe will host a live conference call and webcast for shareholders, analysts and portfolio managers that afternoon at 5:00 PM ET / 2:00 PM PT. Mr. Bajaj and Mr. Goldthorpe will briefly discuss the company's fourth quarter results as well as provide additional commentary on the recently announced strategic investment and commitment made by BC Partners into ContextLogic Holdings, LLC. |
globenewswire.com |
2025-03-10 10:00:00 |
Czytaj oryginał (ang.) |
| ContextLogic Inc. Reports Third-Quarter 2024 Financial Results |
OAKLAND, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- ContextLogic Inc. (Nasdaq: LOGC), (“ContextLogic,” the “Company,” “we” or “our”) today reported its financial results for the quarter and nine months ended September 30, 2024. |
globenewswire.com |
2024-11-07 18:10:00 |
Czytaj oryginał (ang.) |
| ContextLogic Inc. Reports Second-Quarter Financial Results |
OAKLAND, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- ContextLogic Inc. (Nasdaq: LOGC), (“ContextLogic,” the “Company,” “we” or “our”) today reported its financial results for the quarter and six months ended June 30, 2024. |
globenewswire.com |
2024-08-08 20:15:00 |
Czytaj oryginał (ang.) |
| Why Is LogicBio (LOGC) Stock Up 600% Today? |
Source: Roland Magnusson / Shutterstock.com LogicBio (NASDAQ: LOGC ) stock is seeing massive gains on Monday following news that AstraZeneca (NASDAQ: AZN ) subsidiary Alexion is acquiring the clinical-stage genetic medicine company. The deal has Alexion agreeing to a cash tender offer for all outstanding shares of LOGC stock. |
investorplace.com |
2022-10-03 14:33:42 |
Czytaj oryginał (ang.) |
| Why AstraZeneca (AZN) Is Buying LogicBio Therapeutics (LOGC) In About A $68 Million Deal |
LogicBio Therapeutics, Inc. (LOGC) announced it is being acquired in a deal valued at about $68 million. These are the details. |
pulse2.com |
2022-10-03 13:27:43 |
Czytaj oryginał (ang.) |
| 5 Big Winners as Dollar Strengthens on Fed Rate Hike |
A stronger dollar is a boon for Consolidated Water (CWCO), Ashford Hospitality Trust (AHT), BankFinancial (BFIN), LogicBio Therapeutics (LOGC) and ProPhase Labs (PRPH) that have high domestic exposure in terms of revenue generation. |
zacks.com |
2022-09-27 13:47:13 |
Czytaj oryginał (ang.) |
| 5 Winning Stocks Backed by the Overlooked Trick of Rising P/E |
Want to try an out-of-the-box approach? Tap Eastside Distilling (EAST), LogicBio Therapeutics (LOGC), Seabridge Gold (SA), Suzano (SUZ) and J Douglas Emmett (DEI). |
zacks.com |
2022-09-27 13:02:12 |
Czytaj oryginał (ang.) |
| Why LogicBio Therapeutics Shares Are Popping Off Today |
LogicBio Therapeutics Inc (NASDAQ: LOGC) shares are trading higher by 63.48% at $0.81 after the company announced the FDA lifted the clinical hold on its LB-001 Investigational New Drug Application, allowing patient enrollment to resume in the Phase 1/2 SUNRISE trial for pediatric patients with. |
benzinga.com |
2022-05-09 14:26:03 |
Czytaj oryginał (ang.) |
| Stock Market Crash: 4 Penny Stocks To Watch As Dow Slides |
Penny stocks to watch as stock market crash continues. The post Stock Market Crash: 4 Penny Stocks To Watch As Dow Slides appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com. |
pennystocks.com |
2022-05-09 13:22:37 |
Czytaj oryginał (ang.) |
| LogicBio Therapeutics Shares Skyrocket As FDA Lifts Clinical Hold On Its Pediatric Trial |
The FDA has lifted the clinical hold on LogicBio Therapeutics Inc's (NASDAQ: LOGC) LB-001 Investigational New Drug Application (IND) to resume patient enrollment in Phase 1/2 SUNRISE trial in pediatric methylmalonic acidemia patients. Methylmalonic acidemia is an. |
benzinga.com |
2022-05-09 12:50:05 |
Czytaj oryginał (ang.) |
| LogicBio Therapeutics to Present at H.C. Wainwright Gene Therapy and Gene Editing Conference |
LEXINGTON, Mass. , March 23, 2022 /PRNewswire/ -- LogicBio ® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will present a company overview at the H.C. |
prnewswire.com |
2022-03-23 18:30:00 |
Czytaj oryginał (ang.) |
| Why Did LogicBio Therapeutics Shares Plunge To 52-Week Low Today? |
The FDA has placed a clinical hold on LogicBio Therapeutics Inc's (NASDAQ: LOGC) Phase 1/2 SUNRISE trial of LB-001 in pediatric patients with methylmalonic acidemia (MMA). The hold follows after two adolescent patients in the trial were diagnosed with thrombotic microangiopathy (TMA), a clinical syndrome defined by the formation of tiny clots in blood vessels. |
benzinga.com |
2022-02-02 14:34:44 |
Czytaj oryginał (ang.) |
| LogicBio Therapeutics (LOGC): Why The Price Substantially Fell Today |
The stock price LogicBio Therapeutics Inc (NASDAQ: LOGC) fell by over 50% during intraday trading today. This is why it happened. |
pulse2.com |
2022-02-02 12:42:14 |
Czytaj oryginał (ang.) |
| LogicBio Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference |
LEXINGTON, Mass., Sept. 24, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that president and chief executive officer, Fred Chereau, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 8:00 a.m. |
prnewswire.com |
2021-09-24 20:05:00 |
Czytaj oryginał (ang.) |
| LogicBio Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference |
LEXINGTON, Mass., Sept. 10, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that president and chief executive officer Fred Chereau will present a company overview at the H.C. |
prnewswire.com |
2021-09-10 12:00:00 |
Czytaj oryginał (ang.) |
| LogicBio Therapeutics (LOGC) Reports Q2 Loss, Lags Revenue Estimates |
LogicBio Therapeutics (LOGC) delivered earnings and revenue surprises of -32.00% and -83.99%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock? |
zacks.com |
2021-08-09 14:50:26 |
Czytaj oryginał (ang.) |
| LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021 |
LEXINGTON, Mass., July 8, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that Frederic Chereau, chief executive officer of LogicBio, will participate in a virtual panel discussion entitled "Delivery and Durability of Genetic Medicines" at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, 2021 at 10:00 a.m. |
prnewswire.com |
2021-07-08 11:00:00 |
Czytaj oryginał (ang.) |
| LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic Acidemia |
LEXINGTON, Mass., June 2, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that the first patient has been dosed with LB-001, the Company's investigational single-administration gene editing therapy based on its proprietary GeneRide™ platform, in the SUNRISE Phase 1/2 clinical trial in pediatric patients with methylmalonic acidemia (MMA). |
prnewswire.com |
2021-06-02 11:00:00 |
Czytaj oryginał (ang.) |
| LogicBio Therapeutics to Participate in Upcoming Investor Conferences |
LEXINGTON, Mass., June 1, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced that Frederic Chereau, chief executive officer of LogicBio, will participate in virtual fireside chats at the following upcoming investor conferences: Jefferies Virtual Healthcare Conference, Friday, June 4, at 9:30 AM ET. |
prnewswire.com |
2021-06-01 20:05:00 |
Czytaj oryginał (ang.) |
| LogicBio Therapeutics Promotes Daniel Gruskin, MD, to Chief Medical Officer and Announces Additional Leadership Appointments |
LEXINGTON, Mass., May 19, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced the promotion of Daniel Gruskin, MD, as chief medical officer. |
prnewswire.com |
2021-05-19 11:00:00 |
Czytaj oryginał (ang.) |
| LogicBio Therapeutics Reports First Quarter Year 2021 Financial Results and Provides Business Update |
LEXINGTON, Mass., May 10, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today reported financial results for the quarter ended March 31, 2021 and provided a business update. |
prnewswire.com |
2021-05-10 11:30:00 |
Czytaj oryginał (ang.) |